Use in severe hepatic impairment: no dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Kasutamine raske maksapuudulikkuse korral: neeru siirdamisel raske parenhümatoosse maksahaigusega patsientidele ei ole annuseid vaja muuta.